Jackson Creek Investment Advisors LLC Invests $1.56 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jackson Creek Investment Advisors LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,012 shares of the medical equipment provider's stock, valued at approximately $1,563,000.

Several other large investors have also added to or reduced their stakes in LNTH. Avantax Advisory Services Inc. lifted its holdings in Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $237,000. Swiss National Bank boosted its position in shares of Lantheus by 1.0% during the fourth quarter. Swiss National Bank now owns 136,654 shares of the medical equipment provider's stock valued at $12,225,000 after purchasing an additional 1,300 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Lantheus by 39.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 10,814 shares of the medical equipment provider's stock worth $967,000 after purchasing an additional 3,045 shares during the period. Finally, Royce & Associates LP bought a new position in Lantheus in the fourth quarter worth $3,330,000. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LNTH. B. Riley reduced their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $131.20.

Lantheus Stock Down 4.6%

Lantheus stock traded down $3.42 during trading hours on Friday, hitting $70.18. The stock had a trading volume of 1,351,740 shares, compared to its average volume of 980,999. The stock's 50-day moving average price is $78.80 and its 200-day moving average price is $89.44. Lantheus Holdings, Inc. has a 12-month low of $69.12 and a 12-month high of $118.71. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $4.86 billion, a P/E ratio of 19.94 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business's revenue was up .8% compared to the same quarter last year. During the same period last year, the company posted $1.69 earnings per share. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.